- Home
- AMSF vs GHRS Comparison
AMSF vs GHRS Comparison
Compare AMSF & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMSF
- GHRS
- Stock Information
- Founded
- AMSF 1985
- GHRS 2018
- Country
- AMSF United States
- GHRS Ireland
- Employees
- AMSF N/A
- GHRS 50
- Industry
- AMSF Accident &Health Insurance
- GHRS Biotechnology: Pharmaceutical Preparations
- Sector
- AMSF Finance
- GHRS Health Care
- Exchange
- AMSF Nasdaq
- GHRS Nasdaq
- Market Cap
- AMSF 869.6M
- GHRS 930.8M
- IPO Year
- AMSF 2005
- GHRS 2021
- Fundamental
- Price
- AMSF $44.16
- GHRS $15.58
- Analyst Decision
- AMSF Buy
- GHRS Strong Buy
- Analyst Count
- AMSF 2
- GHRS 8
- Target Price
- AMSF $59.50
- GHRS $30.63
- AVG Volume (30 Days)
- AMSF 143.6K
- GHRS 192.1K
- Earning Date
- AMSF 07-24-2025
- GHRS 09-02-2025
- Dividend Yield
- AMSF 10.56%
- GHRS N/A
- EPS Growth
- AMSF N/A
- GHRS N/A
- EPS
- AMSF 2.48
- GHRS N/A
- Revenue
- AMSF $301,216,000.00
- GHRS N/A
- Revenue This Year
- AMSF $1.69
- GHRS N/A
- Revenue Next Year
- AMSF $6.54
- GHRS N/A
- P/E Ratio
- AMSF $17.81
- GHRS N/A
- Revenue Growth
- AMSF N/A
- GHRS N/A
- 52 Week Low
- AMSF $42.48
- GHRS $6.00
- 52 Week High
- AMSF $60.24
- GHRS $20.50
- Technical
- Relative Strength Index (RSI)
- AMSF 47.66
- GHRS 67.14
- Support Level
- AMSF $42.80
- GHRS $14.20
- Resistance Level
- AMSF $44.19
- GHRS $15.54
- Average True Range (ATR)
- AMSF 0.91
- GHRS 1.07
- MACD
- AMSF 0.14
- GHRS 0.29
- Stochastic Oscillator
- AMSF 81.55
- GHRS 93.84
About AMSF AMERISAFE Inc.
AMERISAFE Inc is a specialty provider of workers' compensation insurance focused on small to mid-sized employers engaged in hazardous industries, principally construction, trucking, logging and lumber, agriculture, manufacturing, maritime, and telecommunications. The company generates a majority of its revenue in the form of premiums.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.